Myasthenia gravis
RSS feedThe added value of artificial intelligence in myasthenia gravis remains to be confirmed
Taiwanese researchers conducted an exhaustive analysis of the literature on artificial intelligence (AI) tools in the context of predictive factors at certain stages of myasthenia gravis: a PRISMA-type approach was used to select 11 studies, which focused on prediction tools based on machine learning algorithms, with particular attention paid to admission to intensive care, length … [Read more]
Three case reports suggest the efficacy of eculizumab in dermatomyositis and myasthenic crisis
Already indicated for refractory forms of myasthenia gravis, eculizumab (Soliris®) has been shown to be effective in two other indications: French clinicians, including experts from the Institute, achieved complete and rapid remission in two patients with dermatomyositis when eculizumab was administered in addition to immunosuppressive therapies. The two young women did not relapse after four … [Read more]
Long-term IV immunoglobulins may reduce the incidence of cancer
According to an analysis of follow-up data from 436 patients with autoimmune myasthenia gravis (MG) and 102 with chronic inflammatory demyelinating polyradiculoneuritis (CIDP), receiving intravenous immunoglobulin (IVIg) as maintenance therapy: is associated with a reduction in the incidence of cancers occurring at least one year after diagnosis. this decrease correlates with the duration of IVIg … [Read more]
Genetic factors may influence the risk of developing myasthenia gravis, as well as its expression
A retrospective study of the records of 281 patients with autoimmune myasthenia gravis followed by an Israeli specialist centre between 2000 and 2022 reveals that: 5.7% of them have a first- or second-degree relative with the same disease, a figure almost identical to that of a previous study (5.6%) conducted in the United States. Compared … [Read more]
A pharmacovigilance study on the use of efgartigimod in myasthenia gravis in the United States
Efgartigimod is one of the new molecules used in refractory forms of myasthenia gravis. Chinese researchers have reviewed the side effects recorded in the Food and Drug Administration (FDA) pharmacovigilance database, which is freely accessible in the United States: the study covered the period from the first quarter of 2022 to the fourth quarter of … [Read more]
Encouraging results from the ventilatory weaning protocol during myasthenic crises
French clinicians involved in weaning myasthenic patients undergoing decompensation (myasthenic crisis) report the results of the WEAN Safe protocol applied to a single-center cohort (Paris, Salpêtrière): of the 698 admissions to intensive care for this reason, only the records of 81 patients covering the period 2008-2023 were selected for the study, the median age of … [Read more]
The importance of measuring autoantibodies directed against rituximab in myasthenia gravis
Neurologists in Nice report on their experience in the long-term treatment of autoimmune myasthenia gravis, particularly in the use of a monoclonal anti-CD20 antibody (rituximab or RTX): data from 101 patients with myasthenia gravis treated with RTX as a first- or second-line therapy were included in a retrospective study. Among them, 34 developed autoantibodies directed … [Read more]
Conditioned mesenchymal cells to alleviate Myasthenia Gravis
Mesenchymal stromal cells (MSCs) are promising tools for the treatment of autoimmune and inflammatory diseases. These multipotent stromal cells possess innate immunomodulatory properties that can be significantly enhanced by co-culture with peripheral blood mononuclear cells (PBMCs). Researchers at the Institute’s Center of Research in Myology and their colleagues studied the mechanisms underlying the conditioning of … [Read more]
A new international registry for patients with myasthenia gravis
MGBase is a registry created in 2021 to compile online data on myasthenic patients worldwide: it is directly inspired by a registry developed for multiple sclerosis (MSBase), which collected data from 107,000 patients. In three years, MGBase has recorded the clinical and immunological data of 565 patients with myasthenia gravis included by 16 centres operating … [Read more]
The Danish experience with myasthenia gravis
Danish researchers report the results of a large epidemiological study on mortality observed in myasthenia gravis between 1985 and 2020: the information was drawn from existing health data warehouses in Denmark, mortality figures were defined according to the date of occurrence of the event (within one year [short term], or between 1 and 5 years … [Read more]
